title: Comparision of benefits of early, delayed, and no administration of G-CSF after autologous peripheral blood stem cell transplantation in lymphoma patients.
abstract: BACKGROUND
  Autologous peripheral blood stem cell transplantation (PBSCT) is commonly used in the treatment of lymphoma patients. G-CSF is widely used to boost white blood cell recovery. However, there are no clear data indicating which strategy of using G-CSF provides the most benefit. The aim of our study was to compare 3 strategies of G-CSF administration: from day +1, from day +5, and no administration.
  
  
  METHODS
  Data from 211 patients treated at 3 centers were gathered retrospectively. The patients in the 3 analyzed groups were not different in regard to type of disease, age, sex, and number of CD34+ cells received.
  
  
  RESULTS
  The 3 strategies of G-CSF dosage had very similar results. G-CSF boosted the recovery of white blood cells and shortened the time of neutropenia. However, there were no differences in confirmed infections and the duration of hospitalization after transplantation.
  
  
  CONCLUSIONS
  Our results question the use of G-CSF in a post-PBSCT setting, as it does not provide significant benefits in reducing the number of infections or shortening the duration of hospitalization.
authors.affiliation: Hemato-Oncology Intensive Care Department, Maria Sklodowska-Curie Memorial Cancer Centre in Warsaw, Warsaw, Poland. wylezol@coi.waw.pl
authors.forename: Iwona
authors.initials: I
authors.lastname: Wyleżoł
authors.forename: Emilian
authors.initials: E
authors.lastname: Snarski
authors.forename: Mirosław
authors.initials: M
authors.lastname: Markiewicz
authors.forename: Sławomira
authors.initials: S
authors.lastname: Kyrcz-Krzemień
authors.forename: Wiesław-Wiktor
authors.initials: WW
authors.lastname: Jędrzejczak
authors.forename: Jan
authors.initials: J
authors.lastname: Walewski
mesh_terms: D000328:Adult; D000368:Aged; D064592:Autografts; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006397:Hematinics / Q000008:administration & dosage; D006801:Humans; D017053:Infection Control; D007902:Length of Stay; D007958:Leukocyte Count; D008223:Lymphoma / Q000097:blood / Q000188:drug therapy* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D011044:Poland; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D006397:Hematinics; D016179:Granulocyte Colony-Stimulating Factor